Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Cardiac drug-drug interaction between HCV-NS5B pronucleotide inhibitors and amiodarone is determined by their specific diastereochemistry.

Lagrutta A, Regan CP, Zeng H, Imredy JP, Koeplinger K, Morissette P, Liu L, Wollenberg G, Brynczka C, Lebrón J, DeGeorge J, Sannajust F.

Sci Rep. 2017 Mar 22;7:44820. doi: 10.1038/srep44820.

2.

Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics.

Wolkenberg SE, Nolt MB, Bilodeau MT, Trotter BW, Manley PJ, Kett NR, Nanda KK, Wu Z, Cato MJ, Kane SA, Kiss L, Spencer RH, Wang J, Lynch JJ, Regan CP, Stump GL, Li B, White R, Yeh S, Dinsmore CJ, Lindsley CW, Hartman GD.

Bioorg Med Chem Lett. 2017 Feb 15;27(4):1062-1069. doi: 10.1016/j.bmcl.2016.12.054. Epub 2017 Jan 16.

PMID:
28131713
3.

Assessment of the clinical cardiac drug-drug interaction associated with the combination of hepatitis C virus nucleotide inhibitors and amiodarone in guinea pigs and rhesus monkeys.

Regan CP, Morissette P, Regan HK, Travis JJ, Gerenser P, Wen J, Fitzgerald K, Gruver S, DeGeorge JJ, Sannajust FJ.

Hepatology. 2016 Nov;64(5):1430-1441. doi: 10.1002/hep.28752. Epub 2016 Aug 23.

PMID:
27474787
4.

A comparison of results from a hydrologic transport model (HSPF) with distributions of sulfate and mercury in a mine-impacted watershed in northeastern Minnesota.

Berndt ME, Rutelonis W, Regan CP.

J Environ Manage. 2016 Oct 1;181:74-79. doi: 10.1016/j.jenvman.2016.05.067. Epub 2016 Jun 17.

5.

Characterization of an investigative safety pharmacology model to assess comprehensive cardiac function and structure in chronically instrumented conscious beagle dogs.

Regan CP, Stump GL, Detwiler TJ, Chen L, Regan HK, Gilberto DB, DeGeorge JJ, Sannajust FJ.

J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:107-14. doi: 10.1016/j.vascn.2016.05.002. Epub 2016 May 7.

PMID:
27166580
6.

QT interval correction assessment in the anesthetized guinea pig.

Morissette P, Regan HK, Fitzgerald K, Bernasconi S, Gerenser P, Travis J, Fanelli P, Sannajust F, Regan CP.

J Pharmacol Toxicol Methods. 2015 Sep-Oct;75:52-61. doi: 10.1016/j.vascn.2015.05.007. Epub 2015 May 19.

PMID:
26001325
7.

Comparison of the intrinsic vasorelaxant and inotropic effects of the antiarrhythmic agents vernakalant and flecainide in human isolated vascular and cardiac tissues.

Lynch JJ Jr, Regan CP, Beatch GN, Gleim GW, Morabito CJ.

J Cardiovasc Pharmacol. 2013 Mar;61(3):226-32. doi: 10.1097/FJC.0b013e31827afd29.

PMID:
23188129
8.

MK-0448, a specific Kv1.5 inhibitor: safety, pharmacokinetics, and pharmacodynamic electrophysiology in experimental animal models and humans.

Pavri BB, Greenberg HE, Kraft WK, Lazarus N, Lynch JJ, Salata JJ, Bilodeau MT, Regan CP, Stump G, Fan L, Mehta A, Wagner JA, Gutstein DE, Bloomfield D.

Circ Arrhythm Electrophysiol. 2012 Dec;5(6):1193-201. doi: 10.1161/CIRCEP.111.969782. Epub 2012 Oct 11.

PMID:
23060423
9.

Attenuation of scratch-induced reactive astrogliosis by novel EphA4 kinase inhibitors.

Parmentier-Batteur S, Finger EN, Krishnan R, Rajapakse HA, Sanders JM, Kandpal G, Zhu H, Moore KP, Regan CP, Sharma S, Hess JF, Williams TM, Reynolds IJ, Vacca JP, Mark RJ, Nantermet PG.

J Neurochem. 2011 Sep;118(6):1016-31. doi: 10.1111/j.1471-4159.2011.07375.x. Epub 2011 Aug 16.

10.

Effect of calcitonin gene-related peptide receptor antagonism on the systemic blood pressure responses to mechanistically diverse vasomodulators in conscious rats.

Lynch JJ Jr, Detwiler TJ, Kane SA, Regan CP.

J Cardiovasc Pharmacol. 2010 Nov;56(5):518-25. doi: 10.1097/FJC.0b013e3181f5d414.

PMID:
20729756
11.

Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist.

Bell IM, Gallicchio SN, Wood MR, Quigley AG, Stump CA, Zartman CB, Fay JF, Li CC, Lynch JJ, Moore EL, Mosser SD, Prueksaritanont T, Regan CP, Roller S, Salvatore CA, Kane SA, Vacca JP, Selnick HG.

ACS Med Chem Lett. 2010 Jan 12;1(1):24-9. doi: 10.1021/ml900016y. eCollection 2010 Apr 8.

12.

Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel.

Beshore DC, Liverton NJ, McIntyre CJ, Claiborne CF, Libby B, Culberson JC, Salata JJ, Regan CP, Lynch JJ, Kiss L, Spencer RH, Kane SA, White RB, Yeh S, Hartman GD, Dinsmore CJ.

Bioorg Med Chem Lett. 2010 Apr 15;20(8):2493-6. doi: 10.1016/j.bmcl.2010.03.005. Epub 2010 Mar 4.

PMID:
20304642
13.

Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries.

Lynch JJ Jr, Regan CP, Edvinsson L, Hargreaves RJ, Kane SA.

J Cardiovasc Pharmacol. 2010 May;55(5):518-21. doi: 10.1097/FJC.0b013e3181d7665f.

PMID:
20164785
14.

Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist.

Salvatore CA, Moore EL, Calamari A, Cook JJ, Michener MS, O'Malley S, Miller PJ, Sur C, Williams DL Jr, Zeng Z, Danziger A, Lynch JJ, Regan CP, Fay JF, Tang YS, Li CC, Pudvah NT, White RB, Bell IM, Gallicchio SN, Graham SL, Selnick HG, Vacca JP, Kane SA.

J Pharmacol Exp Ther. 2010 Apr;333(1):152-60. doi: 10.1124/jpet.109.163816. Epub 2010 Jan 11.

PMID:
20065019
15.

Effects of the prototype serotonin 5-HT(1B/1D) receptor agonist sumatriptan and the calcitonin gene-related peptide (CGRP) receptor antagonist CGRP(8-37) on myocardial reactive hyperemic response in conscious dogs.

Lynch JJ, Shen YT, Pittman TJ, Anderson KD, Koblan KS, Gould RJ, Regan CP, Kane SA.

Eur J Pharmacol. 2009 Nov 25;623(1-3):96-102. doi: 10.1016/j.ejphar.2009.09.018. Epub 2009 Sep 17.

PMID:
19766109
16.

The prototype serotonin 5-HT 1B/1D agonist sumatriptan increases the severity of myocardial ischemia during atrial pacing in dogs with coronary artery stenosis.

Lynch JJ Jr, Stump GL, Kane SA, Regan CP.

J Cardiovasc Pharmacol. 2009 Jun;53(6):474-9. doi: 10.1097/FJC.0b013e3181a71a61.

PMID:
19430309
17.

Calcitonin gene-related peptide receptor antagonism does not affect the severity of myocardial ischemia during atrial pacing in dogs with coronary artery stenosis.

Regan CP, Stump GL, Kane SA, Lynch JJ Jr.

J Pharmacol Exp Ther. 2009 Feb;328(2):571-8. doi: 10.1124/jpet.108.144220. Epub 2008 Nov 7.

PMID:
18997059
18.

Long term assessment of blood pressure transducer drift in rhesus monkeys chronically instrumented with telemetry implants.

Regan HK, Lynch JJ, Regan CP.

J Pharmacol Toxicol Methods. 2009 Jan-Feb;59(1):35-8. doi: 10.1016/j.vascn.2008.10.002. Epub 2008 Oct 20.

PMID:
18983927
19.

Attenuation of edema and infarct volume following focal cerebral ischemia by early but not delayed administration of a novel small molecule KDR kinase inhibitor.

Foster KA, Regan HK, Danziger AP, Detwiler T, Kwon N, Rickert K, Lynch JJ, Regan CP.

Neurosci Res. 2009 Jan;63(1):10-6. doi: 10.1016/j.neures.2008.09.007. Epub 2008 Oct 4.

PMID:
18951929
20.
21.

An improved automated method to quantitate infarct volume in triphenyltetrazolium stained rat brain sections.

Regan HK, Detwiler TJ, Huang JC, Lynch JJ, Regan CP.

J Pharmacol Toxicol Methods. 2007 Nov-Dec;56(3):339-43. Epub 2007 Jun 2.

PMID:
17596972
22.

In vivo cardiac electrophysiologic and antiarrhythmic effects of an isoquinoline IKur blocker, ISQ-1, in rat, dog, and nonhuman primate.

Regan CP, Stump GL, Wallace AA, Anderson KD, McIntyre CJ, Liverton NJ, Lynch JJ Jr.

J Cardiovasc Pharmacol. 2007 Apr;49(4):236-45.

PMID:
17438409
23.

Smooth muscle-targeted knockout of connexin43 enhances neointimal formation in response to vascular injury.

Liao Y, Regan CP, Manabe I, Owens GK, Day KH, Damon DN, Duling BR.

Arterioscler Thromb Vasc Biol. 2007 May;27(5):1037-42. Epub 2007 Mar 1.

PMID:
17332489
24.

Design and synthesis of novel isoquinoline-3-nitriles as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation.

Trotter BW, Nanda KK, Kett NR, Regan CP, Lynch JJ, Stump GL, Kiss L, Wang J, Spencer RH, Kane SA, White RB, Zhang R, Anderson KD, Liverton NJ, McIntyre CJ, Beshore DC, Hartman GD, Dinsmore CJ.

J Med Chem. 2006 Nov 30;49(24):6954-7.

PMID:
17125248
25.

Potent antagonists of the Kv1.5 potassium channel: synthesis and evaluation of analogous N,N-diisopropyl-2-(pyridine-3-yl)acetamides.

Nanda KK, Nolt MB, Cato MJ, Kane SA, Kiss L, Spencer RH, Wang J, Lynch JJ, Regan CP, Stump GL, Li B, White R, Yeh S, Bogusky MJ, Bilodeau MT, Dinsmore CJ, Lindsley CW, Hartman GD, Wolkenberg SE, Trotter BW.

Bioorg Med Chem Lett. 2006 Nov 15;16(22):5897-901. Epub 2006 Sep 1.

PMID:
16949818
26.

Block of peripheral nerve sodium channels selectively inhibits features of neuropathic pain in rats.

Brochu RM, Dick IE, Tarpley JW, McGowan E, Gunner D, Herrington J, Shao PP, Ok D, Li C, Parsons WH, Stump GL, Regan CP, Lynch JJ Jr, Lyons KA, McManus OB, Clark S, Ali Z, Kaczorowski GJ, Martin WJ, Priest BT.

Mol Pharmacol. 2006 Mar;69(3):823-32. Epub 2005 Nov 21.

PMID:
16301337
27.

In vivo cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker, (2-Isopropyl-5-methylcyclohexyl) diphenylphosphine oxide, in rat and nonhuman primate.

Regan CP, Wallace AA, Cresswell HK, Atkins CL, Lynch JJ Jr.

J Pharmacol Exp Ther. 2006 Feb;316(2):727-32. Epub 2005 Oct 21.

PMID:
16243963
28.

In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide.

Stump GL, Wallace AA, Regan CP, Lynch JJ Jr.

J Pharmacol Exp Ther. 2005 Dec;315(3):1362-7. Epub 2005 Sep 12.

PMID:
16157659
29.

Novel method to assess cardiac electrophysiology in the rat: characterization of standard ion channel blockers.

Regan CP, Cresswell HK, Zhang R, Lynch JJ.

J Cardiovasc Pharmacol. 2005 Jul;46(1):68-75.

PMID:
15965357
30.

Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects.

Regan CP, Li W, Boucher DM, Spatz S, Su MS, Kuida K.

Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9248-53. Epub 2002 Jul 1.

31.

Selective expression of an endogenous inhibitor of FAK regulates proliferation and migration of vascular smooth muscle cells.

Taylor JM, Mack CP, Nolan K, Regan CP, Owens GK, Parsons JT.

Mol Cell Biol. 2001 Mar;21(5):1565-72.

32.

Molecular mechanisms of decreased smooth muscle differentiation marker expression after vascular injury.

Regan CP, Adam PJ, Madsen CS, Owens GK.

J Clin Invest. 2000 Nov;106(9):1139-47.

35.

Smooth muscle-specific expression of the smooth muscle myosin heavy chain gene in transgenic mice requires 5'-flanking and first intronic DNA sequence.

Madsen CS, Regan CP, Hungerford JE, White SL, Manabe I, Owens GK.

Circ Res. 1998 May 4;82(8):908-17.

PMID:
9576110
36.
38.

Pressure-independent effects of AT1-receptor antagonism on cardiovascular remodeling in aortic-banded rats.

Regan CP, Anderson PG, Bishop SP, Berecek KH.

Am J Physiol. 1997 May;272(5 Pt 2):H2131-8.

PMID:
9176278
39.

Captopril prevents vascular and fibrotic changes but not cardiac hypertrophy in aortic-banded rats.

Regan CP, Anderson PG, Bishop SP, Berecek KH.

Am J Physiol. 1996 Sep;271(3 Pt 2):H906-13.

PMID:
8853324
40.

Salt-induced hypertension in normotensive spontaneously hypertensive rats.

Wyss JM, Roysommuti S, King K, Kadisha I, Regan CP, Berecek KH.

Hypertension. 1994 Jun;23(6 Pt 1):791-6.

PMID:
8206579
41.

Keeping informed.

Regan CP.

Bull Monmouth Ocean Cty Dent Soc. 1972 Dec;31(8):18. No abstract available.

PMID:
4539953
42.

You see what you know (deviate swallowing).

Regan CP.

Bull Monmouth Ocean Cty Dent Soc. 1972 Jan;30(1):9 passim. No abstract available.

PMID:
4536611
43.

Continuing education.

Regan CP.

Dent Econ. 1971 Nov;61(11):9 passim. No abstract available.

PMID:
5287371

Supplemental Content

Loading ...
Support Center